Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that ...

Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock ...

Amgen (AMGN) closed at $434.03 in the latest trading session, marking a +1.86% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.33%. Meanwhile, the Dow ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Cantor Fitzgerald set a USD 440 target from USD 400 on October 8, 2026. Amgen stock was EUR 376.93 on October 13, 2026.

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

Amgen (AMGN) fell over 8%, on track to record its worst single-day decline since 2016 after Novartis (NVS) announced a late-stage trial setback for a heart disease therapy the Swiss company is ...